Skip to main content
SpringerLink
Log in

Family Screening: Who, When and How

  • Chapter
  • First Online:
Hypertrophic Cardiomyopathy

  • 1965 Accesses

Abstract

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant familial cardiac disease. The most devastating presentation of HCM is SCD in a presumed healthy person. The goals of family screening are to identify relatives with unrecognized HCM and to follow at-risk individuals for risk factors of SCD and disease development.

After confirmation of the HCM diagnosis, the patient is informed about the familial character of the disease, the high potential for familial transmission and the possibility to perform genetic testing. Currently the power of genetic testing in HCM lies in identifying family members carrying the genotype (G+) who are at risk for developing disease and excluding unaffected, genotype negative relatives for further cardiac evaluation.

In specialized cardio-genetic outpatient clinics familial and genetic counseling is performed in close collaboration between the cardiologist and the clinical geneticist. Family members at risk are identified and first-degree relatives are informed either via the patient or via direct communication. It is important that ramifications of genetic and/or cardiac testing, especially with regards to health and life insurance, are explained to the family members prior to analysis.

G+ family members and family members of HCM families in which no pathogenic mutation is found are offered longitudinal cardiac evaluation by electrocardiogram and echocardiogram with variable intervals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hollman A, Goodwin JF, Teare D, Renwick JW. A family with obstructive cardiomyopathy (asymmetrical hypertrophy). Br Heart J. 1960;22:449–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Gersh BJ, Maron BJ, Bonow RO, Dearini JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hyperthrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;25:e212–60.

    Article  Google Scholar 

  3. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064–75.

    Article  CAS  PubMed  Google Scholar 

  4. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998;339:364–9.

    Article  CAS  PubMed  Google Scholar 

  5. Corrada D, Pelliccia A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M, et al. Cradiovascular pre-participation screening of young competitive athletes for prevention of sudden cardiac death: proposal for a common European protocol. Eur Heart J. 2005;26:516–24.

    Article  Google Scholar 

  6. Bjornstad H, Corrado D, Pelliccia A. Prevention of sudden death in young athletes: a milestone in the history of sports cardiology. Eur J Cardiovasc Prev Rehabil. 2006;13:857–8.

    Article  PubMed  Google Scholar 

  7. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012;5:552–9.

    Article  CAS  PubMed  Google Scholar 

  8. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8:1308–39.

    Article  PubMed  Google Scholar 

  9. Andreasen C, Nielsen JB, Refsgaard L, Holst AG, Christensen AH, Andreasen L, et al. New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants. Eur J Hum Genet. 2013;21:918–28.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Van Maarle MC, Stouthard ME, Marang-van de Meen PJ, Klazinga NS, Bonsel GJ. How disturbing it is to be approached for a genetic cascade screening programme for familial hypercholesteremia? Community Genet. 2001;4:244–52.

    Article  PubMed  Google Scholar 

  11. Ingles J, Sarina T, Yeates L, Hunt L, Macciocca I, McCormack L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15:972–7.

    Article  PubMed  Google Scholar 

  12. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years. J Am Coll Cardiol. 2012;60:705–15.

    Article  PubMed  Google Scholar 

  13. Hallowell N, Jenkins N, Douglas M, Walker S, Porteous M, et al. Patients’ experiences and views of cascade screening for familial hypercholesterolemia (FH): a qualitative study. J Community Genet. 2011;2:249–57.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J. 2010;31:926–35.

    Article  PubMed  Google Scholar 

  15. Abiola S. Recent developments in health law. The Genetic Information Nondiscrimination Act of 2008. J Law Med Ethics. 2008;36:856–60.

    Article  PubMed  Google Scholar 

  16. Jensen MK, Havndrup O, Christiaensen M, Andersen PS, Diness B, Axelsson A, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents. Circulation. 2013;127:48–54.

    Article  PubMed  Google Scholar 

  17. Ormondroyd E, Oates S, Parker M, Blair E, Watkins H. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychological and ethical implications. Eur J Hum Genet. 2014;22:88–93.

    Article  PubMed  Google Scholar 

  18. Krul SPJ, van der Smagt JJ, van de Berg MP, Sollie KM, Pieper PG, van Spaendonck-Zwarts KY. Systematic review of pregnancy in women with inherited cardiomyopathies. Eur J Heart Fail. 2011;13:584–94.

    Article  PubMed  Google Scholar 

  19. Bratt EL, Ostman-Smith I, Axelsson A, Berntsson L. Quality of life in asymptomatic children and adolescents before and after diagnosis of hypertrophic cardiomyopathy through family screening. J Clin Nurs. 2012;22:211–2.

    Article  PubMed  Google Scholar 

  20. Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy. Am J Med Genet. 2009;149A:602–12.

    Article  PubMed  Google Scholar 

  21. Moak JP, Kaski JP. Hypertrophic cardiomyopathy in children. Heart. 2012;98:1044–54.

    Article  PubMed  Google Scholar 

  22. Delcrè SDL, DiDonna P, Leuzzi S, Miceli S, Bisi M, Scaglione M, et al. Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. Int J Cardiol. 2013;167:1038–45.

    Article  PubMed  Google Scholar 

  23. Maron BJ. The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited. Ann Noninvasive Electrocardiol. 2001;6:277–9.

    Article  CAS  PubMed  Google Scholar 

  24. Ryan MP, Cleland JG, French JA, Joshi J, Choudhury L, Chojnowska L. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol. 1995;76:689–94.

    Article  CAS  PubMed  Google Scholar 

  25. Lakdawala NK, Thune JJ, Maron BJ, Cirino AL, Havndrup O, Bundgaard H, et al. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol. 2011;108:1606–13.

    Article  PubMed Central  PubMed  Google Scholar 

  26. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience form clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997;77:130–2.

    CAS  PubMed Central  PubMed  Google Scholar 

  27. Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle D, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:638–45.

    Article  PubMed  Google Scholar 

  28. Spindler M, Saupe KW, Christe ME, Sweeney HL, Seidman CE, Seidman JG, et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 1998;101:1775–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides novel means for an early diagnosis before and independently of hypertrophy. Circulation. 2001;104:128–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105:2992–7.

    Article  PubMed  Google Scholar 

  31. Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D, et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging. 2009;2:58–64.

    Article  PubMed  Google Scholar 

  32. Valente AM, Lakdawala NK, Powell AJ, Evans SP, Cirino MS, Orav EJ, et al. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013;6:230–7.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:668–73.

    Article  PubMed  Google Scholar 

  34. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40–7.

    Article  CAS  PubMed  Google Scholar 

  35. Germans T, Wilde AA, Dijkmans PA, Chai W, Kamp O, Pinto YM, et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathies mutations. J Am Coll Cardiol. 2006;48:2518–23.

    Article  PubMed  Google Scholar 

  36. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson M, et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5:441–7.

    Article  PubMed  Google Scholar 

  37. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:119–22.

    Article  PubMed  Google Scholar 

  38. Christiaans I, Lekanne dit Deprez RH, Van Langen I, Wilde AAM. Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before the onset of ventricular hypertrophy. Heart Rhythm. 2009;6:1366–9.

    Article  PubMed  Google Scholar 

  39. O’Hanlon R, Grasso A, Rougthon M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867–74.

    Article  PubMed  Google Scholar 

  40. Chan RH, Maron B, Olivotto I, Assenza G, Hong S, Lesser J, et al. Prognostic utility of contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: a multicenter study. JACC. 2012;59:E1570 (abstract).

    Google Scholar 

  41. Christiaans I, Birnie E, Bonsel GJ, Mannens MM, Michels M, Majoor-Krakauer D, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J. 2011;32:1161–70.

    Article  PubMed  Google Scholar 

  42. Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J. 2009;30:2593–8.

    Article  CAS  PubMed  Google Scholar 

  43. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Maron BJ, Zipes DP. 36th Bethesda conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol. 2005;45:1312–75.

    Article  Google Scholar 

  45. Pelliccia A, Corrado D, Bjornstad HH, Panhuyzen-Goedkoop N, Urhausen A, Carre F, et al. Recommendations for participation in competitive sport and leisure-time activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil. 2006;13:876–85.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Erasmus MC Hospital, ‘s-Gravendijkwal 230, Room Ba 350, 2040, 3000, CA, Rotterdam, The Netherlands

    Michelle Michels MD, PhD & Folkert J. ten Cate MD, PhD

Authors
  1. Michelle Michels MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Folkert J. ten Cate MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle Michels MD, PhD .

Editor information

Editors and Affiliations

  1. Winthrop University Hospital, Mineola, New York, USA

    Srihari S. Naidu

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Michels, M., ten Cate, F.J. (2015). Family Screening: Who, When and How. In: Naidu, S. (eds) Hypertrophic Cardiomyopathy. Springer, London. https://doi.org/10.1007/978-1-4471-4956-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4956-9_13

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4955-2

  • Online ISBN: 978-1-4471-4956-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation